Omeprazole, Hypergastrinemia, and Gastric Carcinoid Tumors
Authors: James W. Freston
Journal: Annals of Internal Medicine (1994)

Editorials1 August 1994Omeprazole, Hypergastrinemia, and Gastric Carcinoid TumorsJames W. Freston, MD, PhDJames W. Freston, MD, PhDUniversity of Connecticut Health Center; Farmington, CT 06030Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-121-3-199408010-00012 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The long-term management of reflux esophagitis is challenging because of the frequency of symptomatic relapses and the uncertain efficacy and safety of long-term treatment with acid-suppressing drugs. Reflux esophagitis recurs within 6 months in at least 80% of patients after discontinuation of medical therapy [1]. Thus, some patients, such as those described in this issue by Klinkenberg-Knol and colleagues [2], require continuous therapy with omeprazole. Despite its superior efficacy when compared with histamine-2-(H2) receptor antagonists in healing reflux esophagitis [3] and maintaining remissions [4], clinicians have generally been reluctant to treat patients chronically with omeprazole because of concerns about the ...References1. Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology. 1988; 95:903-12. Google Scholar2. Klinkenberg-Knol EC, Festen HP, Jansen JB, Lamers CB, Nelis F, Snel P, et al. Efficacy and safety of long-term treatment with omeprazole for refractory reflux esophagitis. Ann Intern Med. 1994; 121:161-7. Google Scholar3. Maton PN. Omeprazole. N Engl J Med. 1991; 324:965-75. Google Scholar4. Lundell L, Backman L, Ekstrom P, Enander LK, Falkmer S, Fausa O, et al. Prevention of relapse of reflux esophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine. Scand J Gastroenterol. 1991; 26:248-56. Google Scholar5. Axon AT. The role of acid inhibition in the treatment of Helicobacter pylori infection. Scand J Gastroenterol. 1994; 29(Suppl 201):16-23. Google Scholar6. Brunner G, Creutzfeldt W, Harke U, Lamberts R. Efficacy and safety of long-term treatment with omeprazole in patients with acid-related diseases resistant to ranitidine. Scand J Gastroenterol. 1989; 3(Suppl A):72A-6A. Google Scholar7. Lanzon-Miller S, Pounder RE, Hamilton MR, Ball S, Chronos NA, Raymond F, et al. Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole. Aliment Pharmacol Ther. 1987; 1:239-51. Google Scholar8. McCloy RF. Implications of a review of long-term safety of omeprazole and management strategies for peptic ulcer disease. Hepatogastroenterology. 1992; 39:90-1. Google Scholar9. Lamberts R, Creutzfeldt W, Struber HG, Brunner G, Solcia E. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology. 1993; 104:1356-70. Google Scholar10. Koop H, Arnold R. Long-term maintenance treatment of reflux esophagitis with omeprazole. Prospective study in patients with H2-blocker-resistant esophagitis. Dig Dis Sci. 1991; 36:552-7. Google Scholar11. Larsson H, Hakanson R, Mattsson H, Ryberg B, Sundler F, Carlsson E. Omeprazole: its influence on gastric acid secretion, gastrin and ECL cells. Toxicol Pathol. 1988; 16:267-72. Google Scholar12. Havu N, Mattsson H, Ekman L, Carlsson E. Enterochromaffin-like cell carcinoids in the rat gastric mucosa following long-term administration of ranitidine. Digestion. 1990; 45:189-95. Google Scholar13. Mattson H, Havu N, Brautigam J, Carlsson K, Lundell L, Carlsson E. Partial corpectomy results in hypergastrinemia and development of gastric enterochromaffinlike cell carcinoids in the rat. Gastroenterology. 1991; 100:311-9. Google Scholar14. Borch K, Renvall H, Liedberg G. Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia. Gastroenterology. 1985; 88:638-48. Google Scholar15. Bardram L, Thomsen P, Stadil F. Gastric endocrine cells in omeprazole-treated and untreated patients with the Zollinger-Ellison syndrome. Digestion. 1986; 35(Suppl 1):116-22. Google Scholar16. Axelson J, Hakanson R, Rosengren E, Sundler F. Hypergastrinaemia induced by blockade evokes enterochromaffin-like (ECL) cell hyperplasia in chicken, hamster and guinea-pig stomach. Cell Tissues Res. 1988; 254:511-6. Google Scholar17. Solcia E, Bordi C, Creutzfeldt W, Dayal Y, Dayan AD, Falkmer S, et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion. 1988; 41:185-200. Google Scholar18. Creutzfeldt W, Lamberts R. Is hypergastrinaemia dangerous to man? Scand J Gastroenterol. 1991; 26(Suppl 180):179-91. Google Scholar19. Havu N, Maaroos HI, Sipponen P. Argyrophil cell hyperplasia associated with chronic corpus gastritis in gastric ulcer disease. Scand J Gastroenterol. 1991; 26(Suppl 186):90-4. Google Scholar20. Freston JW. Clinical significance of hypergastrinaemia: relevance to gastrin monitoring during omeprazole therapy. Digestion. 1992; 51(Suppl 1):102-14. Google Scholar21. Sontag S, Robinson M, Roufail W, Berman R, Berlin R, Berger M, et al. Daily omeprazole is needed to maintain healing in erosive esophagitis. A U.S. multicenter double-blind study (Abstract). Am J Gastroenterol. 1992; 87:1258. Google Scholar Author, Article, and Disclosure InformationAuthors: James W. Freston, MD, PhDAffiliations: University of Connecticut Health Center; Farmington, CT 06030 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoLong-Term Treatment with Omeprazole for Refractory Reflux Esophagitis: Efficacy and Safety Elly C. Klinkenberg-Knol , Henk P. M. Festen , Jan B. M. J. Jansen , Cornelis B. H. W. Lamers , Frits Nelis , Pleun Snel , Anton Luckers , Cornelius P. M. Dekkers , Niilo Havu , and Stephan G. M. Meuwissen Metrics Cited byA dual role of proton pump inhibition on cancer: a critical reviewControversial link between proton pump inhibitors and anticancer agents: review of the literatureCalcitonin: current concepts and differential diagnosisAssociation between use of proton pump inhibitors and colorectal cancer: A nationwide population-based studyLong-term use of proton-pump inhibitors and risk of gastric cancer: a review of the current evidenceAdverse Effects of Proton Pump Inhibitors on Platelet Count: A Case Report and Review of the LiteraturePharmacological Reflux TherapiesThe First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic ConsiderationsRisk of gastric cancer, gastrointestinal cancers and other cancers: a comparison of treatment with pantoprazole and other proton pump inhibitorsHypergastrinemiaCalcitonin as Biomarker for the Medullary Thyroid CarcinomaLong-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesionsLong term proton pump inhibitor (PPI) use and incidence of gastric premalignant lesionsCan 2-oxoglutarate prevent changes in bone evoked by omeprazole?Long term proton pump inhibitor (PPI) use and incidence of gastric (pre) malignant lesions.Adverse Effects of Long-Term Proton Pump Inhibitor Use: A Review for the OtolaryngologistGastroesophageal Reflux DiseaseHypercalcitoninemia is not Pathognomonic of Medullary Thyroid CarcinomaLong term proton pump inhibitor (PPI) use and incidence of gastric (pre) malignant lesions.Neuroendocrine Tumors of the Pancreas and Gastrointestinal Tract and Carcinoid DiseaseProton Pump Inhibitor Use and Risk of Colorectal Cancer: A Population-Based, Case–Control StudyManagement of Gastroesophageal Reflux DiseaseConsequences of Long-Term Proton Pump Blockade: Insights from Studies of Patients with GastrinomasLong-term use of acid suppression started inappropriately during hospitalizationClinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: A 13-year prospective studyComparison of Two Provocative Tests for Calcitonin in Medullary Thyroid Carcinoma: Omeprazole vs PentagastrinOne more dysplasiaNeuroendocrine Tumors of the Pancreas and Gastrointestinal Tract and Carcinoid DiseaseStrategies for medical management of reflux diseaseControversies in long-term management of reflux diseaseLong-term proton pump inhibitor therapy accelerates the onset of atrophic gastritis in Helicobacter pylori -positive patientsLaparoscopic management of hiatal hernia and gastroesophageal refluxDeterminants of Initiation and Suboptimal Use of Anti-ulcer Medication: A Study of the Quebec Older PopulationMedical Therapy of GERD: Current State of the ArtPrincipes thérapeutiques du reflux gastroœsophagienIntervening in GERD: The Phases of ManagementThe development of atrophic gastritis-Helicobacter pylori and the effects of acid suppressive therapySevere gastroesophageal reflux diseaseSimplifying the Diagnosis and Treatment of Gastroesophageal Reflux and Airway Diseases 1 August 1994Volume 121, Issue 3Page: 232-233KeywordsCarcinoid tumorCellsGastrinGastritisHypergastrinemiaMultiple endocrine neoplasiaPernicious anemiaReceptor antagonist therapySurgeryZollinger Ellison syndrome ePublished: 15 August 2000 Issue Published: 1 August 1994 Copyright & PermissionsCopyright © 1994 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...